Breaks Categories: News

TuesdaySep 01, 2020 1:26 pm

PsychedelicNewsBreaks — Cybin Corp. Names Health-Care, M&A Expert as New Chief Executive Officer

Cybin Corp., a life-sciences company advancing psychedelic pharmaceuticals, has announced that Doug Drysdale has been appointed as CEO. With more than three decades of experience, Drysdale brings invaluable insight and expertise to his new role. In 2014 as a corporate director of a NASDAQ-listed pharmaceutical company, he led the company’s recapitalization efforts, raising an estimated $65 million. Consequently, he was appointment chairman and CEO and revamped the company’s management team and board of directors while also building a 220-person sales team — all within the first year. Ultimately he grew the company’s enterprise value exponentially from $80 million to around…

Continue Reading

ThursdayAug 27, 2020 2:36 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) to Offer Esketamine for Treatment of Adults with MDD at Flagship Clinic

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced that it is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). According to the update, Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic, the Canadian Rapid Treatment Centre of Excellence (“CRTCE”), starting in September 2020. Declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”), esketamine was approved by Health Canada for the treatment of MDD in May 2020. “The availability of esketamine at the CRTCE provides tremendous opportunity for adults across Canada affected by treatment-resistant depression…

Continue Reading

FridayAug 07, 2020 5:58 pm

PsychedelicNewsBreaks — Cybin Calls Approval for Psilocybin Therapy in Palliative Care Treatment a ‘Watershed Moment’

Cybin Corp., Canada's leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme ("SAP") access to psilocybin therapy for palliative care of Canadians. The coalition recently announced that Federal Minister of Health Patty Hajdu has approved the use psilocybin therapy in the end-of-life care for four Canadians diagnosed with incurable cancer. The four are the first publicly known individuals to legally use psilocybin since the compound became illegal in Canada in 1974. “This is a watershed moment for the patients involved who deserve the right to manage their health…

Continue Reading

WednesdayAug 05, 2020 11:24 am

PsychedelicNewsBreaks – Cybin Corp. Positioned in Shifting Trend Toward Psilocybin

Cybin Corp., Canada's premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products, looks to be at the right place at the right time during a shifting trend toward psilocybin. Highlighting this shift, TheraPsil, a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for palliative Canadians, recently shared news that four palliative Canadians were approved for end-of-life psilocybin therapy. This approval, through section 56(1), represents the first legal medical exemptions for psilocybin in Canada since the 1970s. “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgement…

Continue Reading

MondayJul 27, 2020 9:38 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Files Acquisition Reports, Appoints New Director

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), on Friday announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. The filings are part of Champignon’s commitment to work with the British Columbia Securities Commission to complete its previously announced disclosure review. The Company also announced its appointment of Dr. Roger McIntyre, Champignon CEO, to its Board of Directors. Dr. McIntyre’s appointment will replace Pat McCutcheon’s position as a director of the Company. To view the full press release, visit http://ibn.fm/RDypi About Champignon Brands Inc.…

Continue Reading

MondayJul 13, 2020 10:10 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Corporate Update

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today issued a corporate update. Among other items highlighted in the update, the Company continues to work with the British Columbia Securities Commission (the “Commission”) to complete its continuous disclosure review. Champignon Brands will continue to fully cooperate with the Commission to assist in completion of the review in a timely fashion. In addition, the Company’s board of directors, in June 2020, considered options for realizing additional value for the consumer-packaged goods (“CPG”) pillar of its business and contemplated a reorganization that would result in the spinout of this business into a…

Continue Reading

ThursdayJul 09, 2020 12:18 pm

PsychedelicNewsBreaks – MagicMed Industries Inc. Announces First Psychedelic Derivative Patent Filing in Anticipated Series

MagicMed Industries today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering composition of matter, drug formulation and process of preparation claims for novel psilocybin derivatives. According to the update, the patent filing is anticipated to be the first in a series of applications that together will protect the Company's broad portfolio of novel psilocybin molecular derivatives, the “PsybraryTM.” "We are excited by the new opportunities to partner with pharmaceutical manufacturers afforded by the library of derivatives that this patent application claims," MagicMed CEO and President, Dr. Joseph Tucker, stated…

Continue Reading

TuesdayJul 07, 2020 1:33 pm

PsychedelicNewsBreaks – Cybin Corp. and IntelGenx Corp. to Collaborate in Development of Fast-Acting Psilocybin Film

Cybin Corp., Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, today announced its entry into a feasibility agreement with IntelGenx Corp. (OTCQB: IGXT) (TSX-V:IGX) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals. “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” Cybin’s Chief Medical Officer, Dr. Jukka Karjalainen, stated in the news release. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver,…

Continue Reading

WednesdayJul 01, 2020 1:10 pm

PsychedelicNewsBreaks – Cybin Corp. Announces Reverse Take-Over and Up-To $21M Concurrent Private Placement

Cybin Corp., a mushroom life sciences company focused on psychedelic medicines and nutraceutical products, on Monday announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly-owned subsidiary of Clarmin. According to the update, completion of the transactions contemplated in the agreement will result in the reverse takeover of Clarmin by Cybin (the “Proposed Transaction”). In connection with the Proposed Transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (“Stifel GMP”)…

Continue Reading

MondayJun 29, 2020 1:27 pm

PsychedelicNewsBreaks – Mushrooms Take the Stage in First-Ever PsyTech Summit

The new era of mushrooms was featured in a recent Forbes article by Sara Brittany Somerset titled, “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health.” The article, which discusses psychedelics taking the stage in consumption and investing, reads, “PsychedeliTech, a ground-breaking new conference, incubator and discovery platform for psychedelic medicine will host Rick Doblin, Ph.D., founder and executive director of the Multidisciplinary Association for Psychedelic Studies (“MAPS”) as the keynote speaker at the first-ever PsyTech Summit, a forum for psychedelic science, innovation and investment conference, in Israel.” To view the full article, visit http://ibn.fm/tivNo…

Continue Reading